What is BioScience Health Innovations Inc's earnings per share (EPS)?

BioScience Health Innovations Inc (BHICD) reported diluted earnings per share of $0.06 for fiscal year 2025. This represents a 500.0% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

BioScience Health Innovations Inc Financials

BHICD

Source SEC Filings (10-K/10-Q) Data as of Mar 31, 2026 Currency USD FYE December

This page shows BioScience Health Innovations Inc (BHICD) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 6 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI BHICD FY2025 2026-04-22

Rapid revenue scaling turned accounting profits positive, but the business now looks working-capital hungry rather than cash-light.

FY2025 delivered net income of $642K, yet operating cash flow was only $172K. With cash still near $662K, the company appears working-capital intensive: more of each new sales dollar is being tied up in receivables and inventory before it becomes spendable cash, so earnings quality is improving more slowly than reported profit.

The big structural change is a balance-sheet reset: liabilities are only 13.5% of assets after earlier periods showed negative equity. That leaves a much thicker equity cushion, so current profits are adding to financial staying power instead of merely patching an accumulated deficit, and a lighter liability load gives the company more room to handle uneven cash conversion.

The operating improvement happened alongside gross margin compression to 57.0% from 70.9%, which points away from richer unit economics. The cleaner explanation is overhead absorption: selling and administrative costs did not rise nearly as fast as revenue, so scale is carrying more of the profit load even as each sale contributes a smaller gross slice.

Financial Health Signals

Financial health score pending refresh

We are recalculating BioScience Health Innovations Inc's peer-relative financial health score against the latest fiscal year. It will appear here once the refresh completes. The signals and metrics below are current.

Piotroski F-Score Partial

5/7

BioScience Health Innovations Inc passes 5 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 3 of 4 profitability signals pass, all 1 leverage/liquidity signals pass, 1 of 2 efficiency signals pass.

Earnings Quality Low Quality

0.27x

For every $1 of reported earnings, BioScience Health Innovations Inc generates $0.27 in operating cash flow ($172K OCF vs $642K net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$5.7M

YoY+208.3%

BioScience Health Innovations Inc generated $5.7M in revenue in fiscal year 2025. This represents an increase of 208.3% from the prior year.

EBITDA

N/A

Net Income

$642K

YoY+638.0%

BioScience Health Innovations Inc reported $642K in net income in fiscal year 2025. This represents an increase of 638.0% from the prior year.

EPS (Diluted)

$0.06

YoY+500.0%

BioScience Health Innovations Inc earned $0.06 per diluted share (EPS) in fiscal year 2025. This represents an increase of 500.0% from the prior year.

Cash & Balance Sheet

Free Cash Flow

N/A

Cash & Debt

$662K

YoY-0.1%

5Y CAGR+100.1%

BioScience Health Innovations Inc held $662K in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

11M

YoY+0.0%

5Y CAGR+15.0%

BioScience Health Innovations Inc had 11M shares outstanding in fiscal year 2025. This represents an increase of 0.0% from the prior year.

Margins & Returns

Gross Margin

57.0%

YoY-14.0pp

BioScience Health Innovations Inc's gross margin was 57.0% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is down 14.0 percentage points from the prior year.

Operating Margin

12.6%

YoY+7.9pp

BioScience Health Innovations Inc's operating margin was 12.6% in fiscal year 2025, reflecting core business profitability. This is up 7.9 percentage points from the prior year.

Net Margin

11.3%

YoY+6.6pp

BioScience Health Innovations Inc's net profit margin was 11.3% in fiscal year 2025, showing the share of revenue converted to profit. This is up 6.6 percentage points from the prior year.

Return on Equity

43.5%

YoY+33.0pp

5Y CAGR+103.4pp

BioScience Health Innovations Inc's ROE was 43.5% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 33.0 percentage points from the prior year.

Capital Allocation

R&D Spending

$38K

YoY+44.9%

BioScience Health Innovations Inc invested $38K in research and development in fiscal year 2025. This represents an increase of 44.9% from the prior year.

Share Buybacks

N/A

Capital Expenditures

N/A

BHICD Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	$5.7M+208.3%	$1.8M+208.7%	$598K+761.8%	$69K	$0	$0
Cost of Revenue	$2.4M+356.6%	$536K+373.6%	$113K+1067.0%	$10K	N/A	N/A
Gross Profit	$3.2M+147.6%	$1.3M+170.2%	$484K+712.2%	$60K	N/A	N/A
R&D Expenses	$38K+44.9%	$26K	$0	N/A	N/A	N/A
SG&A Expenses	$2.2M+92.5%	$1.1M+62.3%	$706K+366.7%	$151K+490.9%	$26K+233.4%	$8K
Operating Income	$719K+726.5%	$87K+134.6%	-$252K-47.6%	-$170K-565.6%	-$26K-233.4%	-$8K
Interest Expense	N/A	N/A	N/A	N/A	$450	N/A
Income Tax	$77K	$0	$0	$0	$0	$0
Net Income	$642K+638.0%	$87K+134.6%	-$252K-47.6%	-$170K-565.6%	-$26K-233.4%	-$8K
EPS (Diluted)	$0.06+500.0%	$0.01+200.0%	$-0.01	N/A	N/A	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Revenue	$751K-52.3%	$1.6M+39.0%	$1.1M-35.6%	$1.8M+43.2%	$1.2M+101.1%	$610K+6.5%	$573K+49.1%	$384K
Cost of Revenue	$265K-73.5%	$1.0M+131.0%	$433K-36.6%	$683K+106.4%	$331K+22.0%	$271K+83.0%	$148K+100.9%	$74K
Gross Profit	$486K-15.1%	$572K-18.1%	$698K-35.0%	$1.1M+19.9%	$896K+164.3%	$339K-20.2%	$425K+36.8%	$310K
R&D Expenses	$50K	N/A	N/A	N/A	$38K	N/A	N/A	N/A
SG&A Expenses	$626K-4.6%	$656K+13.8%	$577K+6.8%	$540K+24.6%	$434K+44.4%	$300K-13.1%	$345K+55.1%	$223K
Operating Income	-$230K-46.7%	-$157K-1684.0%	-$9K-101.9%	$458K+7.2%	$427K+4186.4%	$10K-82.3%	$56K-24.3%	$74K
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	$0	N/A
Net Income	-$230K+1.6%	-$234K-2560.3%	-$9K-101.9%	$458K+7.2%	$427K+4186.4%	$10K-82.3%	$56K-24.3%	$74K
EPS (Diluted)	$-0.02	N/A	$0.00	$0.010.0%	$0.01	N/A	$0.01	$0.00

BHICD Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$1.7M+95.4%	$874K+835.7%	$93K+195.5%	$32K+400.6%	$6K-69.4%	$21K
Current Assets	$1.6M+83.9%	$848K+807.8%	$93K+195.5%	$32K+400.6%	$6K-69.4%	$21K
Cash & Equivalents	$662K-0.1%	$663K+3343.8%	$19K+66.3%	$12K+468.5%	$2K-90.1%	$21K
Inventory	$336K+476.7%	$58K+54.7%	$38K+207.1%	$12K	N/A	N/A
Accounts Receivable	$399K+298.1%	$100K+175.1%	$36K+369.6%	$8K	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$230K+496.3%	$39K-61.5%	$100K+105.3%	$49K+155.4%	$19K+144.6%	$8K
Current Liabilities	N/A	N/A	N/A	N/A	N/A	N/A
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$1.5M+76.9%	$835K+12455.6%	-$7K+60.7%	-$17K-34.3%	-$13K-199.8%	$13K
Retained Earnings	$301K+188.3%	-$341K+20.3%	-$428K-142.4%	-$177K-416.4%	-$34K-298.4%	-$9K

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Total Assets	$2.3M+36.5%	$1.7M-17.4%	$2.1M+0.5%	$2.1M+47.5%	$1.4M+59.6%	$874K+110.1%	$416K+94.7%	$214K
Current Assets	$2.2M+40.8%	$1.6M-21.9%	$2.0M+0.5%	$2.0M+48.3%	$1.3M+57.9%	$848K+107.4%	$409K+91.4%	$214K
Cash & Equivalents	$1.1M+73.0%	$662K-41.9%	$1.1M-12.3%	$1.3M+26.4%	$1.0M+55.2%	$663K+98.8%	$333K+131.5%	$144K
Inventory	$874K+160.0%	$336K-55.6%	$758K+204.8%	$249K+15.2%	$216K+269.9%	$58K+38.1%	$42K+4.0%	$41K
Accounts Receivable	$78K-80.4%	$399K+531.6%	$63K-83.8%	$390K+317.4%	$93K-6.8%	$100K+214.2%	$32K+15.5%	$28K
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$646K+180.9%	$230K-35.5%	$356K+5.5%	$338K+154.0%	$133K+244.8%	$39K-15.4%	$46K+85.8%	$25K
Current Liabilities	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$1.7M+14.0%	$1.5M-13.7%	$1.7M-0.5%	$1.7M+36.3%	$1.3M+51.1%	$835K+125.6%	$370K+95.8%	$189K
Retained Earnings	$71K-76.4%	$301K-43.7%	$535K-1.6%	$543K+534.0%	$86K+125.1%	-$341K+2.8%	-$351K+13.8%	-$407K

BHICD Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	$172K+642.5%	$23K+107.5%	-$308K-68.4%	-$183K-520.9%	-$29K-283.2%	-$8K
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	-$57K-118.3%	-$26K	$0	$0	N/A	$0
Financing Cash Flow	-$116K-117.9%	$646K+104.8%	$316K+62.4%	$194K+1691.1%	$11K-61.7%	$28K
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Operating Cash Flow	-$552K-448.3%	-$101K+70.4%	-$340K-219.5%	$285K-13.2%	$328K+752.6%	-$50K-196.3%	$52K-24.6%	$69K
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	$0+100.0%	-$11K	$0+100.0%	-$16K+46.5%	-$30K-57.9%	-$19K-170.0%	-$7K	$0
Financing Cash Flow	$1.0M+382.8%	-$366K-302.8%	$180K+8416.3%	$2K-96.9%	$68K-83.1%	$399K+176.6%	$144K+886.9%	-$18K
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

BHICD Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	57.0%-14.0pp	70.9%-10.1pp	81.1%-4.9pp	86.0%	N/A	N/A
Operating Margin	12.6%+7.9pp	4.7%+46.8pp	-42.1%+203.7pp	-245.8%	N/A	N/A
Net Margin	11.3%+6.6pp	4.7%+46.8pp	-42.1%+203.7pp	-245.8%	N/A	N/A
Return on Equity	43.5%+33.0pp	10.4%	N/A	N/A	N/A	-59.9%
Return on Assets	37.6%+27.6pp	10.0%+279.3pp	-269.3%+269.9pp	-539.3%-133.7pp	-405.6%-368.4pp	-37.2%
Current Ratio	N/A	N/A	N/A	N/A	N/A	N/A
Debt-to-Equity	0.16+0.1	0.05+14.9	-14.81-12.0	-2.84-1.3	-1.49-2.1	0.61
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Gross Margin	64.7%+28.3pp	36.4%-25.4pp	61.7%+0.6pp	61.1%-11.9pp	73.0%+17.5pp	55.6%-18.6pp	74.1%-6.7pp	80.8%
Operating Margin	-30.6%-20.7pp	-10.0%-9.2pp	-0.8%-26.8pp	26.0%-8.7pp	34.8%+33.1pp	1.6%-8.2pp	9.8%-9.5pp	19.3%
Net Margin	-30.6%-15.8pp	-14.8%-14.1pp	-0.8%-26.8pp	26.0%-8.7pp	34.8%+33.1pp	1.6%-8.2pp	9.8%-9.5pp	19.3%
Return on Equity	-13.7%+2.2pp	-15.8%-15.3pp	-0.5%-27.1pp	26.6%-7.2pp	33.8%+32.6pp	1.2%-14.0pp	15.2%-24.1pp	39.3%
Return on Assets	-9.9%+3.8pp	-13.7%-13.3pp	-0.4%-22.7pp	22.3%-8.3pp	30.6%+29.5pp	1.1%-12.4pp	13.5%-21.2pp	34.8%
Current Ratio	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Debt-to-Equity	0.38+0.2	0.16-0.1	0.21+0.0	0.20+0.1	0.11+0.1	0.05-0.1	0.120.0	0.13
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Frequently Asked Questions

What is BioScience Health Innovations Inc's annual revenue?

BioScience Health Innovations Inc (BHICD) reported $5.7M in total revenue for fiscal year 2025. This represents a 208.3% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is BioScience Health Innovations Inc's revenue growing?

BioScience Health Innovations Inc (BHICD) revenue grew by 208.3% year-over-year, from $1.8M to $5.7M in fiscal year 2025.

Is BioScience Health Innovations Inc profitable?

Yes, BioScience Health Innovations Inc (BHICD) reported a net income of $642K in fiscal year 2025, with a net profit margin of 11.3%.

What is BioScience Health Innovations Inc's gross margin?

BioScience Health Innovations Inc (BHICD) had a gross margin of 57.0% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is BioScience Health Innovations Inc's operating margin?

BioScience Health Innovations Inc (BHICD) had an operating margin of 12.6% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is BioScience Health Innovations Inc's net profit margin?

BioScience Health Innovations Inc (BHICD) had a net profit margin of 11.3% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is BioScience Health Innovations Inc's return on equity (ROE)?

BioScience Health Innovations Inc (BHICD) has a return on equity of 43.5% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is BioScience Health Innovations Inc's operating cash flow?

BioScience Health Innovations Inc (BHICD) generated $172K in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are BioScience Health Innovations Inc's total assets?

BioScience Health Innovations Inc (BHICD) had $1.7M in total assets as of fiscal year 2025, including both current and long-term assets.

How much does BioScience Health Innovations Inc spend on research and development?

BioScience Health Innovations Inc (BHICD) invested $38K in research and development during fiscal year 2025.

How many shares does BioScience Health Innovations Inc have outstanding?

BioScience Health Innovations Inc (BHICD) had 11M shares outstanding as of fiscal year 2025.

What is BioScience Health Innovations Inc's debt-to-equity ratio?

BioScience Health Innovations Inc (BHICD) had a debt-to-equity ratio of 0.16 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is BioScience Health Innovations Inc's return on assets (ROA)?

BioScience Health Innovations Inc (BHICD) had a return on assets of 37.6% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is BioScience Health Innovations Inc's Piotroski F-Score?

BioScience Health Innovations Inc (BHICD) has a Piotroski F-Score of 5 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are BioScience Health Innovations Inc's earnings high quality?

BioScience Health Innovations Inc (BHICD) has an earnings quality ratio of 0.27x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.